COMMUNIQUÉS West-GlobeNewswire

Stanford Researchers Presented Results from an Exploratory Study of Serlopitant for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients Indicating Reduction in Itch with Serlopitant Treatment
21/05/2018
Results Presented at the International Investigative Dermatology Meeting REDWOOD CITY, Calif., May 21, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO ), a late-stage biopharmaceutical company focused on [...]
Terveystalo Plc: Managers' Transactions
21/05/2018
TERVEYSTALO PLC MANAGERS' TRANSACTIONS 21 May 2018 at 15:15 EEST ____________________________________________ Person subject to the notification requirement Name: HC TT Holding Oy Ab (Hartwall Capital) Position: Closely [...]
Allscripts closes acquisition of HealthGrid
21/05/2018
Company expands its FollowMyHealth® consumer engagement platform with advanced capabilities CHICAGO, May 21, 2018 (GLOBE NEWSWIRE) -- Allscripts (NASDAQ: MDRX ), a global leader in healthcare technology, today announces [...]
Terveystalo Plc: Managers' Transactions
21/05/2018
TERVEYSTALO PLC MANAGERS' TRANSACTIONS 21 May 2018 at 15:00 EEST ____________________________________________ Person subject to the notification requirement Name: Heinonen, Lasse Position: Member of the Board/Deputy [...]
MimiVax Announces Positive Interim Results from Phase II Trial of SurVaxM Immunotherapy for the Treatment of Newly Diagnosed Glioblastoma
21/05/2018
Interim analysis shows significant survival benefit compared to historical standard of care; Combination of SurVaxM and standard therapy was well-tolerated, with few serious side effects; MimiVax to share findings at [...]
Athenex to Present at UBS Global Healthcare Conference
21/05/2018
BUFFALO, N.Y., May 21, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX ), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
PositiveID to Exhibit its Caregiver Non-Contact Thermometer at the American Association of Critical-Care Nurses Exposition May 22-24
21/05/2018
Caregiver does not come into contact with the patient’s skin nor require probe covers, reducing the risk of cross-contamination and eliminating unnecessary costs DELRAY BEACH, Fla., May 21, 2018 (GLOBE NEWSWIRE) -- [...]
Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. Food and Drug Administration
21/05/2018
First-in-Class Antibody-Drug Conjugate had Received Prior Breakthrough Therapy Designation from the FDA for the Treatment of Metastatic Triple-Negative Breast Cancer MORRIS PLAINS, N.J., May 21, 2018 (GLOBE NEWSWIRE [...]
CLS Holdings USA Expects to Close its Acquisition of Oasis Cannabis by the End of the Second Quarter
21/05/2018
LAS VEGAS, May 21, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB:CLSH) “CLS,” a development stage diversified cannabis company operating as Cannabis Life Sciences, today announced that its proposed acquisition [...]
Inovio Opens Phase 2 Trial for VGX-3100 in Third Indication To Treat HPV – The No. 1 Sexually Transmitted Disease
21/05/2018
Inovio initiates Phase 2 trial for HPV-related anal precancer; already advancing treatment for HPV-caused cervical precancers (Phase 3), and vulvar precancers (Phase 2) PLYMOUTH MEETING, Pa., May 21, 2018 (GLOBE [...]
Akari Therapeutics Receives Notice Related to Delay in 20-F Filing
21/05/2018
NEW YORK and LONDON, May 21, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ: AKTX ), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan [...]
Cidara Therapeutics Announces Offering of Common Stock and Warrants
21/05/2018
SAN DIEGO, May 21, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX ), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has entered into a [...]
MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
21/05/2018
Single Pivotal to Support Registration; Target Enrollment of 220 Patients; Primary Endpoint of Clinical Response Using Peak VO 2 and NYHA Classification Improvements Expected to Initiate in Second Quarter 2018; Topline [...]
Nabriva Therapeutics Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia
21/05/2018
- Lefamulin met all FDA and EMA primary endpoints and was shown to be generally well tolerated - - Company plans to file a New Drug Application with the U.S. Food and Drug Administration in the fourth quarter of 2018 [...]
Allergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging study
21/05/2018
Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Allergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging study - Primary endpoint met with highly [...]
AxoGen, Inc. Announces Appointment of Karen Zaderej as Chairman of the Board
21/05/2018
ALACHUA, Fla., May 21, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN ), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that its Board of Directors [...]
Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
21/05/2018
– FCX-007 well-tolerated up to 52 weeks post-administration – – Continued positive trends noted in wound healing and pharmacology signals, including type VII collagen expression and evidence of anchoring fibrils – – [...]
Microbot Medical Successfully Completes Pre-Clinical Study for its Self-Cleaning Shunt
21/05/2018
Data from Pre-Clinical Study Indicates the Self-Cleaning Shunt has the Potential to be a Viable Technology for Preventing Occlusion in Shunts Used to Treat Hydrocephalus HINGHAM, Mass., May 21, 2018 (GLOBE NEWSWIRE) -- [...]
Avenue Therapeutics Announces Positive Topline Phase 3 Data for Intravenous Tramadol in the Management of Postoperative Pain
21/05/2018
IV tramadol achieved primary and key secondary endpoints, as well as a clear dose response Initiation of second pivotal Phase 3 trial planned for third quarter of 2018 Management to host conference call today at 8:30 a. [...]

Pages